Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minocycline in Clinically Isolated Syndromes (MinoCIS)
NCT00666887Phase 3
Key facts
- Status
- Completed
- Start
- Jan 2009
- Primary completion
- Dec 2014
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- minocycline
- Conditions
- clinically isolated syndrome (CIS)multiple sclerosis (MS)
01
Overview
Phase 3, randomised, double-blind trial in clinically isolated syndrome (CIS) and multiple sclerosis (MS) comparing Minocycline Arm with Placebo Arm (2 arms). Primary endpoint: Conversion of CIS to McDonald Criteria MS at 6 months. Started Jan 2009; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Minocycline Arm
Minocycline 100 mg twice daily for up to 24 months
Placebo Arm
Placebo twice daily for up to 24 months
03
Who it enrols
Patients aged 18-60 with a first focal clinical episode suggestive of demyelinating disease within 180 days and specific MRI lesion criteria (at least two T2 lesions, one of which is ovoid, periventricular, or infratentorial).
04
Endpoints
Primary
Conversion of CIS to McDonald Criteria MS
Secondary
Conversion of CIS to McDonald Criteria MS at 2 years
Change in T2 lesion volume
Cumulative number of enhancing T1 lesions
Cumulative combined unique lesions
Beyond the preview
Go deeper on NCT00666887.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00666887.